UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
SMi's 6th Annual Biomarkers Summit - Innovations Is Stratified Medicine, 16-17 January 2013, London
Date: Oct-02-2012The drive towards personalized medicine is seeing pharma move from patient stratification as a 'nice to have', to an essential feature of product development. Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process. This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity...
Evidence-Based Guidelines Enable Optimal Treatment Of Common Low-Back Pain
Date: Oct-02-2012While scientific evidence suggests that less is typically more when it comes to diagnosing and treating low-back pain in the U.S., the number of expensive imaging exams and surgeries done on patients continues to rise, researchers say. More than 25 percent of American adults report at least one episode of acute low-back pain in the past three months and the annual total price tag is about $100 billion, according to a study in an issue of the Journal of the American College of Radiology focusing on health care reform...
ImmunoGen, Inc. Announces Overall Survival Data Reported For Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial
Date: Oct-02-2012ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, have announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA. Trastuzumab emtansine is in global development by Roche under an agreement between ImmunoGen and Genentech, a member of the Roche Group, and utilizes ImmunoGen's TAP technology with the trastuzumab antibody...
Oral Palonosetron Shows Safe And Effective Control Of Nausea And Vomiting Induced By Multiple Cycles Of Chemotherapy
Date: Oct-02-2012New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile The oral formulation of palonosetron, the second generation 5-HT3 receptor antagonist (5-HT3 RA), is effective and safe in preventing chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of moderate emetogenic chemotherapy (MEC), according to the data presented by Prof Steven Grunberg, Professor of Medicine and Pharmacology, Division of Hematology and Onco...
PERFECT Initiative Shows That Children With Epilepsy May Not Be Receiving Treatment For Prolonged, Acute, Convulsive Seizures
Date: Oct-02-2012Children suffering from prolonged, acute, convulsive seizures may not always receive timely rescue medication in schools and other community settings as intended by their specialist physician, according to the first findings of the PERFECT[1] Initiative. The results were presented as part of a symposium at the ILAE's 10th European Congress on Epileptology (ECE), in London...
Merck Serono: Detailed Results Presented From Study Of Erbitux In Advanced Gastric Cancer (EXPAND)
Date: Oct-02-2012Merck Serono, a division of Merck, Darmstadt, Germany, presented detailed results from the Phase III EXPAND* trial, at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 - October 2, 2012. First results of this study were already announced in July 2012. The results of the Phase III EXPAND trial showed that Erbitux® (cetuximab) in combination with capecitabine and cisplatin did not meet its primary endpoint, progression free survival, in patients with advanced gastric or gastro-esophageal junction cancer compared with chemotherapy alone...
Most Cancer Patients Prepared To Delay Treatment To Benefit From Personalized Care
Date: Oct-02-2012Merck Serono, a division of Merck, Darmstadt, Germany, have announced findings from a new multinational survey of patient awareness and understanding of biomarker-led personalized cancer care presented at the ESMO 2012 Congress (European Society for Medical Oncology). The study - sponsored by Merck - was conducted across several indications, and revealed that whilst the majority of patients surveyed want to be involved in decisions about their treatment, almost a third (32%) are unaware that certain cancers can be tested to determine which treatment could be most suitable for them...
Staffordshire University Tests New Quit Smoking Method
Date: Oct-02-2012Scientists at Staffordshire University have found a cunning way to help young women stop smoking: by showing them a picture of what they would look like a 72 year old smoker. The research, carried out by Professor Sarah Grogan, Professor David Clark-Carter, Keira Flett and other colleagues based at University of Leeds, Nottingham Trent University, University of Canberra and Stoke Primary Care Trust, measured the effects of using the computer ageing technology to show how the study participants would look at age 72 if they continued to smoke...
Will The New EU Pharmacovigilance Legislation Fulfil Its Purpose? 24-25 January 2013, Madrid
Date: Oct-02-2012With the aim of improving the protection of public health, the EU has redefined the practice of pharmacovigilance with new legislation that took effect in July 2012. Better protection of patients by strengthening the EU pharmacovigilance system, enabling citizens to get high-quality information on medicines, and tackling the growing issues of counterfeiting and illegal distribution of medications were said to be the main objectives that stood behind the emergence of the new legislation...
More Trust In Dentists Than Doctors
Date: Oct-02-2012There is a long held view of the traditional family GP widely trusted within the community, always on hand to dish out advice. But new research reveals that dentists are winning the race for trust, as 88 per cent of people surveyed in a new poll3 confirmed that they have a very high degree of trust in their dentist, even greater than in their doctor. The poll, conducted by Bray Leino, also revealed twice as many people (19.7 per cent) value their relationship with their dentist over their doctor (9.9 per cent)...
Stay Connected
